Riliprubart Earns Orphan Drug Designation in the US for Antibody-mediated Rejection in Solid Organ Transplantation
This designation reflects Sanofi’s commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available.
